EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis

Scott D Sagel, Phuong Vu, Sonya L Heltshe, George M Solomon, Andrea Kelly, Jessica Pittman, Margaret Rosenfeld, Felix Ratjen

Journal of Cystic Fibrosis · 2026-05 · 25 (3) · 450-456

DOI: 10.1016/j.jcf.2025.11.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2026-05. Verfasst von Scott D Sagel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, 13123 E. 16th Avenue, B-395, Aurora, CO, USA.…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Chloride Channel Agonists, Cystic Fibrosis, Deoxyribonuclease I. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Limited data exist on the real-world impact of elexacaftor/tezacaftor/ivacaftor (ETI) on use of chronic respiratory therapies. This post-hoc analysis evaluated long-term changes in use of chronic respiratory therapies following ETI initiation among people with (pw)CF aged ≥6 years in the United States and examined characteristics of those who were taking ≥2 chronic therapies at baseline and post-ETI. METHODS: PROMISE is a prospective, multicenter, observational study. Self-reported use of inhaled antibiotics (cycled or continuous), hypertonic saline, dornase alfa, and oral azithromycin were captured before and through 54 months post-ETI initiation in 479 participants ≥12 years and through 36 months post-ETI in 124 participants aged 6-11 years. RESULTS: ETI was associated with reductions in use of four chronic respiratory therapies through 54 months in participants ≥12 years (mean number of therapies decreasing from 2.6 [baseline] to 1.4 [54 months post-ETI]) and 36 months post-ETI in participants aged 6-11 years (mean number of therapies decreasing from 1.9 [baseline] to 1.3 [36 months post-ETI]). Consistent downward trends in use of all four therapies were observed among subgroups based on baseline age strata, sex at birth, prior CFTR modulator use, and ppFEV1. Mean improvements in ppFEV1 and mean changes in respiratory symptoms post-ETI did not differ between participants who remained on ≥2 therapies and participants taking

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsChloride Channel AgonistsCystic FibrosisDeoxyribonuclease ISaline Solution, HypertonicAdolescentChildFemaleHumansMaleAminophenolsAzithromycinBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsIndolesProspective StudiesPyrazolesPyridinesPyrrolidinesQuinolonesRecombinant ProteinsUnited StatesQuinolines

Stichwörter der Autor:innen

CFTR modulatorCystic fibrosisLung functionRespiratory symptomsTreatment burden

Substanzen

AminophenolsAnti-Bacterial AgentsAzithromycinBenzodioxolesCFTR protein, humanChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDeoxyribonuclease Idornase alfaDrug Combinations

Autor:innen und Institutionen

  • Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, 13123 E. 16th Avenue, B-395, Aurora, CO, USA. Electronic address: scott.sagel@childrenscolorado.org.
  • Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA.
  • Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, W…
  • University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Cystic Fibrosis Foundation

Zitieren

APA

Sagel, S. D., Vu, P., Heltshe, S. L., Solomon, G. M., Kelly, A., Pittman, J., Rosenfeld, M., & Ratjen, F. (2026). Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. Journal of Cystic Fibrosis, 25(3), 450-456. https://doi.org/10.1016/j.jcf.2025.11.016

Vancouver

Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, et al. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. Journal of Cystic Fibrosis. 2026;25(3):450-456. doi:10.1016/j.jcf.2025.11.016

BibTeX
@article{Sagel2026,
  author = {Sagel, Scott D and Vu, Phuong and Heltshe, Sonya L and Solomon, George M and Kelly, Andrea and Pittman, Jessica and Rosenfeld, Margaret and Ratjen, Felix},
  title = {Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {3},
  pages = {450--456},
  doi = {10.1016/j.jcf.2025.11.016}
}
Kostenlos starten →